Trade Show News | Zhaoyan New Drug to Attend the 7th ADC and Novel Antibody Drug Development Summit

(Source: Zhaoyan JOINN)

The 7th ADC and Novel Antibody Drug Development Summit will be grandly kicked off at the JunJia Renaissance Hotel in Shanghai on April 1-2, 2026. The conference brings together decision-makers and thought leaders from MNCs, capital, clinical, biotech, and research institutions, and will cover the entire industry chain of ADC and novel antibody drug R&D, production, and application, spanning four core segments: pharmaceutical R&D, clinical healthcare, industrial manufacturing, and capital investment. As spring warms and flowers bloom, it is the time to get together. On April 1-2, 2026, we look forward to meeting you in Shanghai!

Zhao Yanfang, Project Leader of the In Vitro Biology Department, Drug Discovery Business Unit at Beijing Zhaoyan New Drug Research Center Co., Ltd., will attend this conference and deliver a keynote speech titled “Building an In Vitro Biological Evaluation System for ADC Drugs and Key Technology Applications.” At that time, Zhaoyan New Drug will also set up an exhibition booth (Booth No. #A5), providing a detailed introduction to the company’s solutions across the entire drug lifecycle—welcoming industry peers to come for exchange and discussion.

Zhaoyan New Drug · Speech

Speech Title

“Building an In Vitro Biological Evaluation System for ADC Drugs and Key Technology Applications”

Forum

A2 Innovative Target Exploration and Combination Therapy

Speech Time

April 1, 2026 16:20

Speech Abstract

1）Introduction: Background of ADC drugs and the importance of in vitro evaluation

2）In vitro evaluation system: Multidimensional validation and mechanism research

3）Case analysis: Evaluation examples for HER2 and Claudin18.2 targets

4）Summary and outlook: Key strategies and future development directions

Zhao Yanfang

Beijing Zhaoyan New Drug Research Center Co., Ltd.

Project Leader of the In Vitro Biology Department, Drug Discovery Business Unit

Mainly responsible for building and operating the in vitro biological evaluation platform, and carrying out core work such as target validation, method development, and high-throughput screening of small-molecule drugs.

Mr./Ms. Zhao has been engaged in in vitro biological R&D testing for 16 years, with more than 9 years of multi-system CRO service experience. They have collaborated with 100+ large pharmaceutical companies at home and abroad, and have delivered outstanding performance in the in vitro biological screening and evaluation work for multiple IND-submitted drugs.

Zhaoyan New Drug (Share Code: 603127.SH / 6127.HK) was established in 1995 and is one of the earliest enterprise-based organizations in China engaged in non-clinical drug evaluation. The company has established animal testing facilities and supporting laboratories that meet international standards in Beijing, Suzhou, Guangzhou, and in the U.S. states of California and Boston, with a total area of over 200,000 square meters. It is the largest non-clinical CRO enterprise in China in terms of scale and the most complete service capability.

The company has the qualifications of CNAS/ILAC accreditation and has passed comprehensive GLP inspections in China, the U.S., Europe, Japan, and South Korea, and has also obtained international AAALAC animal welfare accreditation, thereby building a quality management system that meets international standards. Its business scope covers drug discovery, non-clinical evaluation, clinical trial services (Phases I-IV), pharmaceutical quality testing, and post-market re-evaluation, providing support for research across the entire drug lifecycle; it also provides safety evaluation services for laboratory animals, model animals, as well as for pesticides, veterinary drugs, and medical devices.

Adhering to the mission of “serving pharmaceutical innovation, focusing on safety evaluation and monitoring throughout the entire drug lifecycle,” Zhaoyan is committed to ensuring patients’ medication safety and caring for human health.

For a wealth of information and precise insights, all on the Sina Finance APP